Curis, Inc. (NASDAQ:CRIS) shares traded down 16.3% during mid-day trading on Tuesday . The stock traded as low as $0.82 and last traded at $0.82. 5,705,558 shares traded hands during mid-day trading, an increase of 157% from the average session volume of 2,221,696 shares. The stock had previously closed at $0.98.
Separately, Zacks Investment Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $7.00.
The company has a debt-to-equity ratio of 1.49, a current ratio of 4.56 and a quick ratio of 4.56.
Curis (NASDAQ:CRIS) last issued its earnings results on Thursday, March 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.04. The firm had revenue of $3.26 million for the quarter, compared to the consensus estimate of $2.03 million. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. sell-side analysts forecast that Curis, Inc. will post -0.38 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its stake in shares of Curis by 1,341.7% in the fourth quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock worth $2,204,000 after buying an additional 2,930,725 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Curis by 1,816.6% during the fourth quarter. Two Sigma Investments LP now owns 854,944 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 810,336 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Curis by 1,591.5% during the fourth quarter. Two Sigma Advisers LP now owns 331,922 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 312,299 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Curis by 136.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 504,371 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 290,812 shares during the last quarter. Finally, Thrivent Financial For Lutherans purchased a new position in shares of Curis during the fourth quarter valued at approximately $108,000. Hedge funds and other institutional investors own 48.14% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/03/15/curis-cris-shares-down-16-3.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.